Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/21000
PROSPECTIVE EVALUATION OF SERUM CONCENTRATIONS OF FERRITIN AND C-REACTIVE PROTEIN IN PULMONARY TB PATIENTS UNDERGOING ANTI-TUBERCULOUS THERAPY
Author
Affilliation
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório de Integrado de Microbiologia e Imunoregulação. Unidade de Medicina Investigativa. Salvador, BA, Brasil
Federal University Rio de Janeiro. University Hospital Clementino Fraga Filho. Medicine School. Research Center in Infectious and Parasitic Diseases. Molecular Micobacteriology Laboratory. Rio de Janeiro, RJ, Brazil
Federal University Rio de Janeiro. University Hospital Clementino Fraga Filho. Medicine School. Research Center in Infectious and Parasitic Diseases. Molecular Micobacteriology Laboratory. Rio de Janeiro, RJ, Brazil
Ary Parreira Institute. State Secretary of Health of Rio de Janeiro. Rio de Janeiro, RJ, Brazil
State University of North Fluminense Darcy Ribeiro. Center of Bioscience and Biotechnology. Recognize the Biology Laboratory. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. School of Medicine. Tuberculosis Academic Program. Rio de Janeiro, RJ, Brazil
Amsterdam Institute for Global Health and Development. Academic Medical Centre. Amsterdam, The Netherlands
Amsterdam Institute for Global Health and Development. Academic Medical Centre. Amsterdam, The Netherlands
Fundação Oswaldo Cruz. Centro de Desenvolvimento de Tecnologia em Saúde. Rio de Janeiro, RJ, Brazil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório de Integrado de Microbiologia e Imunoregulação. Unidade de Medicina Investigativa. Salvador, BA, Brasil
Federal University Rio de Janeiro. University Hospital Clementino Fraga Filho. Medicine School. Research Center in Infectious and Parasitic Diseases. Molecular Micobacteriology Laboratory. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. School of Medicine. Tuberculosis Academic Program. Rio de Janeiro, RJ, Brazil
Federal University Rio de Janeiro. University Hospital Clementino Fraga Filho. Medicine School. Research Center in Infectious and Parasitic Diseases. Molecular Micobacteriology Laboratory. Rio de Janeiro, RJ, Brazil
Federal University Rio de Janeiro. University Hospital Clementino Fraga Filho. Medicine School. Research Center in Infectious and Parasitic Diseases. Molecular Micobacteriology Laboratory. Rio de Janeiro, RJ, Brazil
Ary Parreira Institute. State Secretary of Health of Rio de Janeiro. Rio de Janeiro, RJ, Brazil
State University of North Fluminense Darcy Ribeiro. Center of Bioscience and Biotechnology. Recognize the Biology Laboratory. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. School of Medicine. Tuberculosis Academic Program. Rio de Janeiro, RJ, Brazil
Amsterdam Institute for Global Health and Development. Academic Medical Centre. Amsterdam, The Netherlands
Amsterdam Institute for Global Health and Development. Academic Medical Centre. Amsterdam, The Netherlands
Fundação Oswaldo Cruz. Centro de Desenvolvimento de Tecnologia em Saúde. Rio de Janeiro, RJ, Brazil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório de Integrado de Microbiologia e Imunoregulação. Unidade de Medicina Investigativa. Salvador, BA, Brasil
Federal University Rio de Janeiro. University Hospital Clementino Fraga Filho. Medicine School. Research Center in Infectious and Parasitic Diseases. Molecular Micobacteriology Laboratory. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. School of Medicine. Tuberculosis Academic Program. Rio de Janeiro, RJ, Brazil
Abstract
Tuberculosis (TB) is a leading cause of death worldwide. Unsuccessful sputum culture conversion at month 2 of treatment has been proposed as risk factor for treatment failure and relapse. Several biomarkers have been evaluated with culture conversion. Experimental data suggest a role for anemia and iron in the course of TB infection. However, there is limited evidence on the potential effects of anemia of inflammation and iron deficiency or iron overload on the TB treatment.
Share